HERG篩檢市場規模、佔有率和成長分析（按類型、離子通道、應用和地區分類）—2026-2033 年產業預測

預計到 2024 年，全球 HERG篩檢市場規模將達到 17.9 億美元，到 2025 年將達到 20 億美元，到 2033 年將達到 48.8 億美元，在預測期（2026-2033 年）內，複合年成長率為 11.8%。

全球HERG基因篩檢市場正經歷顯著成長，其主要驅動力是人們對藥物安全性的日益關注以及對更高效篩檢方法的需求。製藥和生技產業是這一趨勢的關鍵促進者，它們尋求可靠的技術來降低藥物誘發心律不整的風險。人們對藥物心臟毒性的認知不斷提高，凸顯了HERG基因篩檢在藥物研發過程中的重要性。自動化膜片鉗系統和高通量篩檢等技術進步正在推動市場擴張。此外，嚴格的監管要求迫使製藥公司投資HERG基因篩檢以確保合規性。然而，先進篩檢設備所需的高額初始投資對中小企業和研究機構構成了挑戰。此外，準確預測心臟安全性仍然十分複雜，需要持續的研究。

全球HERG篩檢市場促進因素

對藥物安全性的日益重視是全球HERG基因篩檢市場的主要驅動力，促使各公司投入資源研發創新篩檢技術。這項投資旨在在藥物研發早期識別具有潛在心臟毒性風險的化合物。隨著監管壓力的增加和對安全藥物需求的不斷成長，各機構逐漸認知到有效HERG基因篩選在降低藥物篩檢風險的重要性。因此，對藥物安全性的關注不僅推動了調查方法的進步，也提高了上市新型治療化合物的整體療效和可靠性。

限制全球HERG篩檢市場的因素

全球HERG篩檢市場面臨的一大挑戰是先進篩檢設備（例如自動化膜片鉗系統）的部署和維護成本高昂。這一巨大的經濟障礙為中小型製藥公司和研究機構帶來了挑戰，限制了它們獲得尖端HERG基因篩檢技術的機會。因此，這些機構可能會落後於能夠更輕鬆地投資必要硬體和資源的大型競爭對手，最終影響它們在藥物研發領域的創新和新藥開發能力。這種經濟限制可能會阻礙整體市場成長和關鍵篩檢方法的進步。

全球HERG篩檢市場趨勢

隨著越來越多的公司尋求高效的解決方案來評估藥物安全性，全球HERG篩檢市場正經歷著向自動化和高通量技術的顯著轉變。消費者對潔淨標示產品的日益關注，推動了對嚴格篩檢流程的需求，以識別藥物化合物中潛在的HERG風險。自動化膜片鉗系統因其高通量和精確的測量能力而備受關注，能夠實現更有效率的藥物研發流程。這種對高通量篩檢（HTS）技術的關注，使研究人員能夠同時評估大量化合物，最終加速開發更安全的治療方案，並加強業界的監管合規性。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究分析

全球HERG篩檢市場規模（按類型和複合年成長率分類）（2026-2033年）

• 基因 KCNH2
• 突變體KCNH2

全球HERG篩檢市場規模（依離子通道及複合年成長率分類）（2026-2033年）

• 電壓依賴性
• 配體依賴性

全球HERG篩檢市場規模（依應用及複合年成長率分類）（2026-2033年）

• 抗心律不整藥物
• 抗精神病藥物
• 抗生素
• 其他

全球HERG篩檢市場規模（按地區分類）及複合年成長率（2026-2033年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Cytocentrics AG（Germany）
• Charles River Laboratories（US）
• Thermo Fisher Scientific Inc.（US）
• PerkinElmer Inc.（US）
• Eurofins Scientific SE（Luxembourg）
• Nanion Technologies GmbH（Germany）
• SB Drug Discovery（UK）
• B'SYS GmbH（Switzerland）
• RedShift BioAnalytics, Inc.（US）
• Icagen, Inc.（a division of Eurofins DiscoverX）（US）
• Apredica（a division of Eurofins DiscoverX）（US）
• Inotrem SA（France）
• Axxam SpA（Italy）
• Ncardia AG（Germany）

結論與建議

Global HERG Screening Market size was valued at USD 1.79 Billion in 2024 and is poised to grow from USD 2 Billion in 2025 to USD 4.88 Billion by 2033, growing at a CAGR of 11.8% during the forecast period (2026-2033).

The global hERG screening market is experiencing significant growth driven by heightened focus on drug safety and the demand for more efficient screening methods. The pharmaceutical and biotechnology sectors are key contributors to this trend, as they seek reliable technologies to mitigate the risk of drug-induced cardiac arrhythmias. Increased awareness of drug cardiotoxicity has underscored the importance of hERG screening in the drug development process. Advances in technologies, including automated patch clamp systems and high-throughput screening, are propelling market expansion. Additionally, stringent regulatory demands urge pharmaceutical companies to invest in hERG screening to ensure compliance. However, the high initial investment for sophisticated screening equipment poses a challenge for smaller companies and research institutions, while accurately predicting cardiac safety remains complex, necessitating ongoing research.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global HERG Screening market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global HERG Screening Market Segments Analysis

Global HERG Screening Market is segmented by Type, Ion Channel, Application and region. Based on Type, the market is segmented into Gene KCNH2 and Mutant KCNH2. Based on Ion Channel, the market is segmented into Voltage-Gated and Ligand-Gated. Based on Application, the market is segmented into Antiarrhythmic, Antiphyshotic, Antibiotics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global HERG Screening Market

The growing focus on ensuring drug safety serves as a primary catalyst for the Global HERG Screening market, prompting companies to allocate resources toward innovative screening technologies. This investment is aimed at identifying potential compounds that may have adverse cardiac effects early in the drug discovery process. As regulatory pressures increase and the demand for safe pharmaceuticals rises, organizations recognize the importance of effective HERG screening in mitigating risks associated with drug development. Consequently, this emphasis on drug safety not only fosters advancements in screening methodologies but also enhances the overall efficacy and reliability of new therapeutic compounds entering the market.

Restraints in the Global HERG Screening Market

A significant challenge facing the Global HERG Screening market is the high cost associated with obtaining and maintaining advanced screening equipment, such as automated patch clamp systems. This substantial financial hurdle poses difficulties for smaller pharmaceutical companies and research institutions, limiting their access to cutting-edge hERG screening technologies. As a result, these organizations may struggle to keep pace with larger competitors that can more easily invest in necessary hardware and resources, ultimately impacting their capacity for innovation and research within the field of drug development. Such economic constraints can restrict overall market growth and the advancement of critical screening methodologies.

Market Trends of the Global HERG Screening Market

The Global HERG Screening market is experiencing a significant trend towards automation and high-throughput technologies, as companies increasingly seek efficient solutions for assessing drug safety profiles. The rising consumer awareness of clean label products has heightened the demand for rigorous screening processes to identify potential hERG liabilities in pharmaceutical compounds. Automated Patch Clamp Systems are gaining traction due to their capability for high throughput and precise measurements, streamlining the drug discovery workflow. This focus on High-Throughput Screening (HTS) technology enables researchers to evaluate numerous compounds simultaneously, ultimately accelerating the development of safer therapeutic options and enhancing regulatory compliance in the industry.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Study Analysis

Global HERG Screening Market Size by Type & CAGR (2026-2033)

• Market Overview
• Gene KCNH2
• Mutant KCNH2

Global HERG Screening Market Size by Ion Channel & CAGR (2026-2033)

• Market Overview
• Voltage-Gated
• Ligand-Gated

Global HERG Screening Market Size by Application & CAGR (2026-2033)

• Market Overview
• Antiarrhythmic
• Antiphyshotic
• Antibiotics
• Others

Global HERG Screening Market Size & CAGR (2026-2033)

• North America (Type, Ion Channel, Application)
  • US
  • Canada
• Europe (Type, Ion Channel, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Ion Channel, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Ion Channel, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Ion Channel, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Cytocentrics AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific SE (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nanion Technologies GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SB Drug Discovery (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B'SYS GmbH (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RedShift BioAnalytics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Icagen, Inc. (a division of Eurofins DiscoverX) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Apredica (a division of Eurofins DiscoverX) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inotrem S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axxam S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ncardia AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations